GlassScriptPhysician profile
Jessica B Rushing
NPI 1023414141
$6,503.81
in general payments reported to CMS, 2019-2025
26 companies · $1,873 in 2025
The $1,873 reported for 2025 was more than what 92% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $384 · 2022: $609 · 2023: $2,172 · 2024: $1,466 · 2025: $1,873.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,073 · Consulting Fee: $1,000 · Education: $438.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,072.61 |
| Consulting Fee | $1,000.00 |
| Education | $437.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,415.65 | 2021-2025 | Otezla, Otezla |
| Janssen Biotech, INC. | $855.17 | 2023-2025 | Tremfya, Simponi, Simponi Aria |
| Sun Pharmaceutical Industries INC. | $745.38 | 2022-2025 | Ilumya, Winlevi, Absorica Ld |
| Novartis Pharmaceuticals Corporation | $736.57 | 2021-2025 | |
| Galderma Laboratories, L.P. | $513.52 | 2021-2025 | Aklief, Oracea, Epsolay |
| Abbvie INC. | $503.43 | 2022-2025 | |
| Genzyme Corporation | $335.19 | 2023-2025 | |
| Incyte Corporation | $313.11 | 2022-2025 | Opzelura |
| E.R. Squibb & Sons, L.L.C. | $147.66 | 2021-2025 | Sotyktu |
| Sanofi-Aventis U.S. LLC | $144.00 | 2021-2024 | |
| Regeneron Healthcare Solutions, INC. | $94.23 | 2023-2024 | Dupixent |
| Arcutis Biotherapeutics, INC. | $92.66 | 2024-2025 | Zoryve |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $71.48 | 2022-2025 | Jublia, Arazlo, Duobrii |
| Medline Industries LP | $70.49 | 2025 | |
| Ucb, INC. | $66.98 | 2023-2025 | Bimzelx, Cimzia |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $63.83 | 2023-2025 | Taltz, Olumiant, Ebglyss |
| Mayne Pharma Commercial LLC | $59.02 | 2023-2025 | |
| Paratek Pharmaceuticals, INC. | $54.23 | 2023-2024 | Nuzyra |
| Botanix Sb INC | $48.42 | 2025 | Sofdra |
| Pfizer INC. | $44.61 | 2021-2023 | |
| Journey Medical Corporation | $35.28 | 2024-2025 | |
| Almirall LLC | $20.11 | 2024 | Seysara |
| Lnhc, INC | $19.33 | 2025 | Zelsuvmi |
| Biocon Biologics INC | $19.15 | 2025 | Yesintek |
| Dermavant Sciences, INC. | $17.96 | 2024 | Vtama |
| Verrica Pharmaceuticals INC. | $16.35 | 2024 | Ycanth |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jessica Rushing listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.